Ärzte haben festgestellt, dass Clopidogrel, ein allgemein verschriebenes Blutverdünner, besser ist als Aspirin, um Herzinfarkte und Striche zu verhindern, und ohne zusätzliches Risiko
https://www.theguardian.com/society/2025/aug/31/doctors-find-drug-that-is-better-than-aspirin-at-preventing-heart-attacks-clopidogrel
9 Kommentare
> The international team of medics behind the study, from countries including the US, UK, Australia, Switzerland and Japan, said the results showed that clopidogrel was “superior” to aspirin and should lead to “extensive adoption” of the drug in clinical practice worldwide.
>Their comprehensive analysis of nearly 29,000 patients with coronary artery disease (CAD) found that clopidogrel was better than aspirin in preventing serious heart and stroke events, without increasing the risk of major bleeding.
>The analysis drew from diverse patient groups, including those who had undergone procedures such as stent placement or had experienced acute coronary syndrome, and examined various subgroups to ensure the findings applied broadly.
>
>Notably, even patients who might respond less well to clopidogrel as a result of genetic or clinical factors still benefited from its use over aspirin. The results suggest that clopidogrel should be considered the preferred long-term anti-platelet medication for patients with CAD.
>
>Because both medications are widely available, the findings have the potential to influence clinical guidelines worldwide and improve patient outcomes. Further research on the cost-effectiveness of clopidogrel, as well as broader population studies, will be needed to support changes in treatment standards.
[Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis – The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01562-4/abstract)
Blood thinner better at thinning blood than analgesic.
Imagine…
“No extra risk” doesn’t mean much here because aspirin ODs are way deadlier than people generally realize. If it had to go thru modern FDA approval there’s no way it would be OTC.
Congrats pharma companies, this will be a successful cash grab.
– Superiority in medicine requires more than 29,000 patients, this is also a study for „Secondary prevention“ and should NOT be expanded to patients without prior heart disease history (primary vs secondary prevention).
– And, one of them is OTC? There is no „superiority“ that can overcome the real world limitations of „Needing to see a doctor or prescriber in order to obtain“
– This is a pharma driven cash grab. Full goddamn stop.
Not surprising but being on blood thinners sucks compared to aspirin. I’ve been on them twice for a month after a stroke and I both bruised like a peach and would bleed from every knick and scrape for hours. Thankfully they were only for a month and then I switched back to aspirin.
Another example why this sub should not allow posts other than the primary research.
The article mistakenly implies primary prevention when this is specifically secondary prevention, I.e., in patients that already have known cardiovascular disease. We already don’t recommend aspirin for primary prevention.
This is already known in stroke literature. We often times combine aspirin and Plavix for 3 weeks per the chance, point, atamis studies. But beyond that there is often increased risk of bleeding.
Also there are a ton of people who are Plavix non responders due to different enzymatic activity, predominantly in Asian populations. So it’s far from a miracle drug.
Aspirin. Isn’t. A. Blood. Thinner. Hope this helps.
There’s a reason like 99% of patients that go through the Cath lab are on aspirin and/or plavix or brilinta. With many also on eliquis or various statins. Most seem to be on more than just one of them.